RegisterLogin

AZD1897

CAT: 0804-HY-164460-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-164460-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC50 values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib (HY-15431) . This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways[1][2].
CAS Number
[1204181-93-0]
UNSPSC
12352005
Target
Pim
Type
Reference compound
Related Pathways
JAK/STAT Signaling
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/azd1897.html
Purity
99.69
Solubility
DMSO : 20 mg/mL (ultrasonic; warming; adjust pH to 2 with 1 M HCl; heat to 60°C)
Smiles
O=C(NC/1=O)SC1=C/C2=CC=CC(OC(C)C)=C2N3C[C@H](N)CCC3
Molecular Formula
C18H23N3O3S
Molecular Weight
361.46
References & Citations
[1]Dakin LA, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett. 2012 Jul 15;22 (14) :4599-604. |[2]Meja K, et al. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. Br J Haematol. 2014 Oct;167 (1) :69-79.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PIM1; PIM2; PIM3

Related Products

CatalogName
HY-15950-01AZD1981
HY-121070AZD1092
HY-126329-01AZD9898
HY-50914-01AZD5597
HY-109566-01AZD1390
HY-U00257-01AZD1979
HY-13224-01AZD4877
HY-15950R-01AZD1981 (Standard)
HY-13224AAZD4877 (hydrochloride)

Alternative Products

CatalogName

Popular Products